Majority of the company`s revenues come from insulin and formulation sales. Other products like Brufen and Digene pertain to their respective therapeutic segments. The company`s product portfolio provides therapies for both acute and chronic health conditions.
It is engaged in pharmaceutical formulations including tablets, liquids, injectibles and capsules, and nutritional products including powder. The installed capacity for tablets is 450 million, while for liquids it is 5,185 Kilo liter, and for capsules 46 million. The powder has an installed capacity of 600 tons. However, the company produced 25 million tablets, 1,141 kiloliters of liquids and 29 million capsules.
It is the company`s strategy to continue to focus on its core therapeutic areas in pharmaceuticals, viz, CNS, gastroenterology, metabolic, pain management, urology, specialized anesthesia range and neonatology. Growth in chronic therapy areas is expected to continue while innovations and life cycle management will continue to support the performance of the company in acute therapy segments. The performance of Abbott India is in line with trends observed in the market, viz., good growth in chronic disease areas. However, the volumes in acute therapy areas such as gastroenterology and pain management continue to be under pressure.
The company plans to augment its R&D activities by focusing on new product development, improvement in the present formulations/process, and improving operational efficiencies. The company now employs approximately 65,000 people and markets its products in 130 countries worldwide. Abbott India has a network of 18 distribution points, which cater to 11,000 stockists and 70,000 retailers. Financials Abbott India registered a 34.66% growth in net profit to Rs 183 million for the quarter ended May 2007 from a profit of Rs 135.9 million for the quarter ended May 2006. Net sales rose 18.8% to Rs 1,540.4 million for the quarter ended May 2007 from Rs 1,296.6 million for the quarter ended May 2006. Total income rose 20.19% to Rs 1,618.7 million for the quarter ended May 2007 from Rs 1,346.8 million for the quarter ended May 2006. The earnings per share (EPS) of the company stood at Rs 12.65 for the quarter ended May 2007.
It is engaged in pharmaceutical formulations including tablets, liquids, injectibles and capsules, and nutritional products including powder. The installed capacity for tablets is 450 million, while for liquids it is 5,185 Kilo liter, and for capsules 46 million. The powder has an installed capacity of 600 tons. However, the company produced 25 million tablets, 1,141 kiloliters of liquids and 29 million capsules.
It is the company`s strategy to continue to focus on its core therapeutic areas in pharmaceuticals, viz, CNS, gastroenterology, metabolic, pain management, urology, specialized anesthesia range and neonatology. Growth in chronic therapy areas is expected to continue while innovations and life cycle management will continue to support the performance of the company in acute therapy segments. The performance of Abbott India is in line with trends observed in the market, viz., good growth in chronic disease areas. However, the volumes in acute therapy areas such as gastroenterology and pain management continue to be under pressure.
The company plans to augment its R&D activities by focusing on new product development, improvement in the present formulations/process, and improving operational efficiencies. The company now employs approximately 65,000 people and markets its products in 130 countries worldwide. Abbott India has a network of 18 distribution points, which cater to 11,000 stockists and 70,000 retailers. Financials Abbott India registered a 34.66% growth in net profit to Rs 183 million for the quarter ended May 2007 from a profit of Rs 135.9 million for the quarter ended May 2006. Net sales rose 18.8% to Rs 1,540.4 million for the quarter ended May 2007 from Rs 1,296.6 million for the quarter ended May 2006. Total income rose 20.19% to Rs 1,618.7 million for the quarter ended May 2007 from Rs 1,346.8 million for the quarter ended May 2006. The earnings per share (EPS) of the company stood at Rs 12.65 for the quarter ended May 2007.
You can make money daily using our Bank Nifty Trading Strategy and it requires a small capital of Rs 5000-10000 to get started and become a part of pro traders league.
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
